ClinicalTrials.gg
Active, not recruitingNCT02531516Updated Nov 3, 2026

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

A Phase 3 interventional study of Apalutamide and Bicalutamide in Prostatic Neoplasms, sponsored by Aragon Pharmaceuticals, Inc.. Active, not recruiting at 263 sites in 23 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,503
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
3rd of 70
1,503 · median 81
Started
2015
with 2 others
Phase 3
16 of 70
2 open now
Primary completion
2027-03
later than 23 of 35 live
Registered
9th of 70
by date
Lead sponsor
9 of 70
Aragon Pharmaceuticals, Inc.

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 16 in phase 3, reaches primary completion later than 23 of the 35 other live ones, and was the 9th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) based on conventional imaging assessed by blinded independent central review (BICR).

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Prostatic neoplasms
  • Prostate Cancer
  • High-Risk prostate cancer
  • JNJ-56021927
  • Apalutamide
  • ATLAS
  • Radiation
  • Long-term hormone therapy
  • Localized or locally advanced prostate cancer
  • Janssen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age >= 18 years
  • Indicated and planned to receive primary radiation therapy for prostate cancer
  • confirmed adenocarcinoma of an intact prostate, and 1 of the following at diagnosis: 1) Gleason score >=8 and >=cT2c, 2) Gleason score 7, PSA >=20 nanogram per milliliters (ng/mL), and >=cT2c
  • Charlson index (CCI) \<=3
  • An (ECOG) Performance Status (PS) grade of 0 or 1
  • Adequate organ function: (1) (AST), alanine aminotransferase (ALT), within normal limits (WNL), (2) serum creatinine less than (\<) 1.5 milligram/deciliter (mg/dL) (\<133 micromoles/Liter [mcmol/L]), (3) greater than or equal to (>=)140,000/microLiter (mcL), independent of transfusion and/or growth factors within 3 months prior to randomization, (4) >= 12.0 gram/deciliter (g/dL) (7.4 millimloes [mmol], independent of transfusion and/or growth factors within 3 months prior to randomization
  • Participants who are sexually active (even men with vasectomies) and willing to use a condom and agree not to donate sperm during the trial
  • Signed, written,
  • Be able to swallow whole study drug tablets

Exclusion Criteria: -

  • Presence of distant , (clinical stage M1). Isolated pelvic nodal disease below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal disease (clinical N stage; N1 versus N0) will be assessed by central radiological review. Patients are considered eligible only if the central radiological review confirms clinical stage M0
  • Prior treatment with gonadotropin releasing hormone (GnRH) analogue or anti-androgen or both for >3 months prior to randomization
  • Bilateral orchiectomy
  • History of pelvic radiation
  • Prior systemic (example [e.g.], chemotherapy) or local (e.g. radical prostatectomy, cryotherapy) treatment for prostate cancer
  • History of seizure or any condition that may predispose to seizure (including, but not limited to prior stroke, or loss of consciousness \<= 1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
  • Prior treatment with enzalutamide, abiraterone acetate, orteronel, galeterone, ketoconazole, aminoglutethimide, estrogens, megestrol acetate, and progestational agents (including cyproterone acetate) for prostate cancer
  • Prior treatment with radiopharmaceutical agents (e.g., strontium-89) or immunotherapy (e.g., sipuleucel-T) for prostate cancer
  • Prior treatment with systemic ≤4 weeks prior to randomization or is expected to require long-term use of corticosteroids during the study
  • Use of 5-alpha reductase inhibitors (e.g., dutasteride, finasteride) \<=4 weeks prior to randomization
  • Use of any agent \<=4 weeks prior to randomization
  • Current chronic use of opioid analgesics for >=3 weeks for oral or >= 7 days for non-oral formulations
  • Major surgery \<=4 weeks prior to randomization
  • Current or prior treatment with anti-epileptic medications for the treatment of seizures
  • Gastrointestinal conditions affecting absorption
  • Known or suspected or to apalutamide, bicalutamide or GnRH agonists or any of the components of the formulations
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,503 participants (actual)

Study arms

  • Experimental
    Apalutamide

    Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.

    Drug: Apalutamide · Drug: Bicalutamide Placebo · Drug: GnRH (agonist) · Radiation: 74-80 Grays (units of radiation)

  • Active comparator
    Control group

    Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.

    Drug: Bicalutamide · Drug: Apalutamide Placebo · Drug: GnRH (agonist) · Radiation: 74-80 Grays (units of radiation)

Interventions

06

What researchers measure

Primary outcomes

  1. Metastasis-Free Survival (MFS)

    MFS is defined as the time from randomization to the date of the first occurrence of radiographic bone or soft tissue distant metastasis based on conventional imaging assessed by blinded independent central review (BICR), histopathologic diagnosis of distant metastasis, or death from any cause, whichever occurs first.

    Time frame: 108 Months

Secondary outcomes

  1. Event-Free Survival (EFS) Based on Conventional Imaging Assessed By BICR

    EFS is defined as the time from randomization to the date of the first occurrence of prostate specific antigen (PSA) failure by the Phoenix definition, local or regional disease recurrence based on conventional imaging assessed by BICR or histopathologic diagnosis, distant metastasis based on conventional imaging assessed by BICR or histopathologic diagnosis, or death.

    Time frame: 108 Months

  2. Time to PSA Progression

    Time to PSA progression is defined as the time from randomization to the date of PSA nadir plus (+) 0.5 nanograms per milliliter (ng/mL) and rising.

    Time frame: 108 Months

  3. MFS Based on Conventional Imaging or Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) Imaging Assessed by BICR

    MFS is defined as the time from randomization to the date of the first occurrence of radiographic bone or soft tissue distant metastasis based on conventional imaging assessed by BICR or PSMA-PET imaging assessed by BICR, histopathologic diagnosis of distant metastasis, or death from any cause, whichever occurs first.

    Time frame: 108 Months

  4. No Evidence of Disease (NED) Based on Conventional Imaging or PSMA PET Imaging Assessed by BICR

    NED is defined as: alive; no PSA progression; no distant metastasis based on conventional imaging assessed by BICR or PSMA-PET imaging assessed by BICR or histopathologic diagnosis; no local or regional recurrence based on conventional imaging assessed by BICR or PSMA-PET imaging assessed by BICR, or histopathologic diagnosis; no subsequent therapy for prostate cancer; testosterone recovery to age-related pre-androgen deprivation therapy (pre-ADT)/baseline or greater than (\>) 200 nanogram per deciliter (ng/dL).

    Time frame: 108 Months

  5. Overall Survival (OS)

    OS is defined as the time from randomization to date of death from any cause.

    Time frame: 108 Months

  6. Time to Distant Metastasis Based on Conventional Imaging Assessed by BICR

    Time to distant metastasis is defined as the time from randomization to the date of the first occurrence of radiographic or pathological bone or soft tissue distant metastasis based on conventional imaging assessed by BICR or histopathologic diagnosis of distant metastasis.

    Time frame: 108 Months

  7. EFS Based on Conventional Imaging or PSMA-PET Imaging Assessed by BICR

    EFS is defined as the time from randomization to the date of the first occurrence of PSA failure by the Phoenix definition, local or regional disease recurrence based on conventional imaging assessed by BICR or PSMA-PET imaging assessed by BICR or histopathologic diagnosis, distant metastasis based on conventional imaging assessed by BICR or PSMA-PET imaging assessed by BICR or histopathologic diagnosis, or death.

    Time frame: 108 Months

  8. Time to Next Local or Systemic Treatment

    Time to next local or systemic treatment is defined as the time from randomization to the first subsequent therapy, including re-initiation of androgen deprivation therapy (ADT) and local treatments for local-regional recurrence or distant metastasis.

    Time frame: 108 Months

07

Study locations

263 sites
  • Homewood, Alabama, United States
  • Chandler, Arizona, United States
  • Scottsdale, Arizona, United States
  • Tucson, Arizona, United States
  • Bakersfield, California, United States
  • Los Angeles, California, United States
  • Orange, California, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • San Francisco, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • Middlebury, Connecticut, United States
  • Bradenton, Florida, United States
  • Daytona Beach, Florida, United States
  • Fort Myers, Florida, United States
  • Hialeah, Florida, United States
  • Lakewood Rch, Florida, United States
  • Naples, Florida, United States
  • Plantation, Florida, United States
  • Meridian, Idaho, United States
  • Evergreen Park, Illinois, United States
  • Harvey, Illinois, United States
  • Jeffersonville, Indiana, United States
  • Wichita, Kansas, United States
  • Ashland, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Scarborough, Maine, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • St Louis, Missouri, United States
  • Morristown, New Jersey, United States
  • Albany, New York, United States
  • Brooklyn, New York, United States
  • New York, New York, United States
  • Poughkeepsie, New York, United States
  • Rochester, New York, United States
  • Syracuse, New York, United States
  • The Bronx, New York, United States
  • Cary, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Portland, Oregon, United States
  • Springfield, Oregon, United States
  • Bala-Cynwyd, Pennsylvania, United States
  • Bryn Mawr, Pennsylvania, United States
  • Lancaster, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • East Greenwich, Rhode Island, United States
  • Charleston, South Carolina, United States
  • Myrtle Beach, South Carolina, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Fairfax, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Burien, Washington, United States
  • Spokane, Washington, United States
  • Morgantown, West Virginia, United States
  • Buenos Aires, Argentina
  • C.a.b.a., Argentina
  • Caba, Argentina
  • Pergamino, Argentina
  • Rosario, Argentina
  • San Salvador de Jujuy, Argentina
  • Aalst, Belgium
  • Antwerp, Belgium
  • Bonheiden, Belgium
  • Brussels, Belgium
  • Haine Saint Paul La Louviere, Belgium
  • Leuven, Belgium
  • Liège, Belgium
  • Namur, Belgium
  • Roeselare, Belgium
  • Sint-Niklaas, Belgium
  • Turnhout, Belgium
  • Barretos, Brazil
  • Belo Horizonte, Brazil
  • Campinas, Brazil
  • Curitiba, Brazil
  • Florianópolis, Brazil
  • Goiânia, Brazil
  • Ijuí, Brazil
  • Natal, Brazil
  • Porto Alegre, Brazil
  • Ribeirão Preto, Brazil
  • Rio de Janeiro, Brazil
  • Salvador, Brazil
  • Santo André, Brazil
  • São José do Rio Preto, Brazil
  • São Paulo, Brazil
  • Sorocaba, Brazil
  • Calgary, Alberta, Canada
  • Surrey, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Victoria, British Columbia, Canada
  • London, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada

Showing the first 100 of 263 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Poterala JE, Wisinski KB. Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy. Cancer. 2022 May 1;128(9):1724-1726. doi: 10.1002/cncr.34158. Epub 2022 Feb 25. No abstract available. PubMed 35213039 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2015 (actual). Primary completion is estimated for Mar 2027, 135 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 135 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2015
First posted
Aug 24, 2015
StartActual
Nov 19, 2015
Primary completionEst.
Mar 1, 2027
CompletionEst.
Dec 29, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 25, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02531516
Responsible party
Sponsor
First posted
Aug 24, 2015
Start date
Nov 19, 2015
Primary completion
Mar 1, 2027 (estimated)
Completion
Dec 29, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Aragon Pharmaceuticals, Inc. Clinical Trial
study director · Aragon Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion